This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Gynaecology, Women's Sexual Health and Benign Breast Disease



October 2021

Estetrol for treating vasomotor symptoms

Estetrol is currently in development for the treatment of vasomotor symptoms experienced during the menopause. Vasomotor symptoms, mainly categorised as hot flushes, are often described as a sudden feeling of heat that spreads throughout the body. They can cause intense embarrassment and inconvenience to women with reports of a reduced quality of life for women …


June 2021

Relugolix combination therapy for treating endometriosis-associated pain

Relugolix in combination with estradiol and norethindrone is currently in clinical development for the treatment of endometriosis-associated pain. Endometriosis is a common, long-term gynaecological disorder where the tissue that normally lines the womb (endometrium) grows in other places. When this tissue breaks down as part of the normal menstrual cycle it becomes trapped in a …


July 2020

Relugolix in combination with estradiol/norethindrone acetate for moderate to severe symtpoms of uterine fibroids

Relugolix is a small molecule that binds to the gonadotropin-releasing hormone receptor in the pituitary gland, decreasing the release of hormones which control oestrogen and progesterone production by the ovaries. Results from clinical trials demonstrated that relugolix in combination with estradiol and norethisterone acetate reduced menstrual bleeding in women with uterine fibroids. Relugolix is administered orally, and if licensed would offer an additional treatment option for women moderate to severe symptoms associated with uterine fibroids.


July 2018

Leuprorelin acetate for the preservation of ovarian function in premenopausal women with neoplastic disease undergoing chemotherapy

Leuprorelin acetate is a gonadotropin-releasing hormone (GnRH) analogue that may preserve ovarian function by preventing early stage development of ovarian follicles from maturation. This may decrease the number of follicles that are vulnerable to chemotherapy. The protective effects of GnRH analogues have also been associated with a decrease in utero-ovarian blood flow which leads to decreased exposure of the ovaries to the chemotherapeutic agents. If licensed, leuprorelin acetate, given by injection, may offer a simpler, less invasive and less expensive alternative when compared to current strategies for preserving ovarian function in women undergoing chemotherapy.


November 2016

FlexDex Needle Driver for minimally invasive laparoscopic surgical suturing

The FlexDex Needle Driver, developed by FlexDex, Inc., is a laparoscopic instrument intended for use in all patients undergoing laparoscopic surgical procedures requiring intensive suturing.


September 2015

Sonata™ System for the removal of uterine fibroids

The Sonata™ System (previously VizAblate®), developed by Gynesonics, is an incisionless, transcervical system that combines ultrasound image guidance with radiofrequency (RF) ablation. The system is designed to treat symptomatic uterine fibroids in a hospital outpatient setting, depending on anaesthetic requirements.


November 2014

SoftVue™ system for diagnostic breast imaging

The SoftVue™ system developed by Delphinus Medical Technologies is a non-ionising, non-compressing, and non-invasive whole breast imaging device. Its intended use is for the examination of breasts for the presence of suspicious masses. It is not intended for use as a replacement of screening mammography.


March 2014

Lyrette™ for stress urinary incontinence

Lyrette™, formerly known as Renessa, is a transurethral device developed by Verathon Medical Ltd to deliver non-ablative radiofrequency energy to women with stress urinary incontinence (SUI) caused by hypermobility. It is intended to provide a treatment option for SUI before invasive surgery.


August 2013

PartoSure™ Time to Delivery test in suspected premature labour

PartoSure™ Time to Delivery (TTD) test is a novel, rapid point-of-care test, developed by AmniSure International (a QIAGEN company). The test is designed to help predict the time to delivery when pregnant women report signs and symptoms suggestive of labour between 20 and 37 weeks of gestation with clinically intact amniotic membranes.


August 2013

IceSense3™ Cryoablation System for breast fibroadenoma

The IceSense3™ Cryoablation System, developed by IceCure Medical Ltd., is a device which uses extreme cold (cryoablation) to treat symptomatic breast fibroadenoma (benign breast tumour).

Get Alerts